~~and~~ wherein the amount of the ~~diphtheria toxoid used as an immunogenic antigen of~~ *Corynebacterium diptheriae* immunogenic antigen ~~of~~ is ~~between~~ 4-16 Lf per ml.

2. (Amended) The vaccine as claimed in claim 1, ~~characterized in that~~ wherein the amount of diphtheria ~~toxoid~~ immunogenic antigen is about 10 Lf per ml.

3. (Amended) The vaccine as claimed in claim 1 ~~or 2~~, ~~in which~~ wherein the amount of tetanus ~~toxoid~~ immunogenic antigen is about 20 Lf per ml.

4. (Amended) The vaccine as claimed in ~~any one of claims 1 to 3~~claim 1, ~~also~~ further comprising at least one antigen ~~chosen~~ selected from the group consisting of *Bordetella pertussis*, hepatitis A and hepatitis B antigens.

9. (Amended) A pharmaceutical kit comprising at least 2 injectable doses of ~~a~~ the vaccine as claimed in ~~one of claims 1 to 4~~claim 1.

10. A method for immunizing a human against at least ~~the~~ poliovirus, *Corynebacterium diphtheriae* and *Clostridium tetani*, the method comprising ~~the administration of a~~ administering to the person a vaccine as claimed in ~~any one of claims 1 to 4~~claim 1.

11. (Amended) ~~A primary immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the~~ deep subcutaneous or intramuscular ~~route~~injection~~, preferably via the intramuscular route in the deltoid region,~~ in 3 doses ~~of said vaccine, preferably at 0.5 ml~~, the first two doses being administered 1 to 2 months apart~~,~~ and the third dose being administered 6 to 12 months after the injection of the second dose.